share_log

百花医药(600721.SH):预计半年度净利润同比增加35.38%到103.08%

Xinjiang Bai Hua Cun Pharma Tech (600721.SH) expects net income to increase by 35.38% to 103.08% in the first half of the year.

Gelonghui Finance ·  Jul 10 04:36

On July 10th, Gelunhui reported that, according to preliminary calculations by the company's finance department, it is expected to achieve a net income attributable to shareholders of the listed company of 176 million yuan to 264 million yuan in the first half of 2024, an increase of 4.6 million yuan to 13.4 million yuan compared with the same period last year, a year-on-year increase of 35.38% to 103.08%. The company expects to achieve a net profit after deducting non-recurring gains and losses attributable to the shareholders of the listed company of 165 million yuan to 245 million yuan in the first half of 2024, an increase of 34.40% to 99.56% compared with the same period last year.

Compared with the same period last year, the company further shrinks accounting units, refines incentive assessments, improves the efficiency of R&D projects, increases the number of R&D projects, shortens the project delivery period, allows fixed costs to be spread out, and increases project gross profit, leading to the growth of the company's profits.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment